NYSE:BIOA

Bioamber Stock Insider Trading

*Your capital is at risk

$16.04

-0.500 (-3.02%)

At Close: Jun 03, 2026

BioAmber Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -48.29. In total, the insiders bought 6.45M and sold 378.12K BIOA shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-48.29
● Buy	6.45M shares
● Sell	378.12K shares
89% Buy Activity Moderate Negative Correlation
Buy Signal Low Confidence Feb 17, 2026 Analysis Breakdown: Signal is highly questionable due to a strongly contradictory negative Insider Power Score of -48.29. Confidence increased due to high data reliability score of 100. Supported by overwhelming buy-side pressure (89% buys).

Historical Insider Trades

Date	Type	Person	Role	Amount
Apr 23, 2026 Buy	Common Stock M-Exempt	Goldstein Dov A Md Chief Financial Officer	C-Suite Officer	3 542 Value: $15.5K
Apr 23, 2026 Buy	Stock Option (Right to Buy) M-Exempt	Goldstein Dov A Md Chief Financial Officer	C-Suite Officer	3 542 Value: $15.5K
Apr 01, 2026 Buy	Stock Option (Right to Buy) M-Exempt	Rubin Paul D Chief Medical Officer	Officer	3 383 Value: $22.2K
Apr 01, 2026 Buy	Stock Option (Right to Buy) M-Exempt	Rubin Paul D Chief Medical Officer	Officer	5 437 Value: $22.3K
Apr 01, 2026 Sell	Common Stock S-Sale	Rubin Paul D Chief Medical Officer	Officer	8 820 Value: $157.1K
Apr 01, 2026 Buy	Common Stock M-Exempt	Rubin Paul D Chief Medical Officer	Officer	5 437 Value: $22.3K
Apr 01, 2026 Buy	Common Stock M-Exempt	Rubin Paul D Chief Medical Officer	Officer	3 383 Value: $22.2K
Mar 02, 2026 Sell	Common Stock S-Sale	Rubin Paul D Chief Medical Officer	Officer	7 433 Value: $150.9K
Mar 02, 2026 Buy	Stock Option (Right to Buy) M-Exempt	Rubin Paul D Chief Medical Officer	Officer	2 000 Value: $13.1K
Mar 02, 2026 Buy	Common Stock M-Exempt	Rubin Paul D Chief Medical Officer	Officer	5 433 Value: $22.3K
Mar 02, 2026 Buy	Stock Option (Right to Buy) M-Exempt	Rubin Paul D Chief Medical Officer	Officer	5 433 Value: $22.3K
Mar 02, 2026 Buy	Common Stock M-Exempt	Rubin Paul D Chief Medical Officer	Officer	2 000 Value: $13.1K
Mar 01, 2026 Buy	Common Stock M-Exempt	Goldstein Dov A Md Chief Financial Officer	C-Suite Officer	3 542 Value: $15.5K
Mar 01, 2026 Buy	Stock Option (Right to Buy) M-Exempt	Goldstein Dov A Md Chief Financial Officer	C-Suite Officer	3 542 Value: $15.5K
Feb 17, 2026 Buy	Stock Option (Right to Buy) A-Award	Barton Shane Principal Accounting Officer	Officer	45 000 Value: $883.4K
Feb 17, 2026 Buy	Stock Option (Right to Buy) A-Award	Fortney Kristen Chief Executive Officer	CEO / President	330 000 Value: $6.48M
Feb 17, 2026 Buy	Stock Option (Right to Buy) A-Award	Goldstein Dov A Md Chief Financial Officer	C-Suite Officer	110 000 Value: $2.16M
Feb 17, 2026 Buy	Stock Option (Right to Buy) A-Award	Morgen Eric Chief Operating Officer	C-Suite Officer	12 500 Value: $245.4K
Feb 17, 2026 Buy	Stock Option (Right to Buy) A-Award	Morgen Eric Chief Operating Officer	C-Suite Officer	110 000 Value: $2.16M
Feb 17, 2026 Buy	Stock Option (Right to Buy) A-Award	Rubin Paul D Chief Medical Officer	Officer	110 000 Value: $2.16M
Feb 02, 2026 Sell	Common Stock S-Sale	Rubin Paul D Chief Medical Officer	Officer	7 433 Value: $139.4K
Feb 02, 2026 Buy	Stock Option (Right to Buy) M-Exempt	Rubin Paul D Chief Medical Officer	Officer	2 000 Value: $13.1K
Feb 02, 2026 Buy	Common Stock M-Exempt	Rubin Paul D Chief Medical Officer	Officer	5 433 Value: $22.3K
Feb 02, 2026 Buy	Common Stock M-Exempt	Rubin Paul D Chief Medical Officer	Officer	2 000 Value: $13.1K
Feb 02, 2026 Buy	Stock Option (Right to Buy) M-Exempt	Rubin Paul D Chief Medical Officer	Officer	5 433 Value: $22.3K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT BIOAMBER INC

BioAmber Inc., an industrial biotechnology company, produces and sells bio-succinic acid to various chemical market customers in the United States. Its proprietary technology platform combines industrial biotechnology and chemical catalysis to convert renewable feedstocks into chemicals that are replacements for petroleum-derived chemicals. The companys bio-succinic acid is used in various applications, including plasticizers, polyurethanes, pe...

Read Full Profile Here